ID | 1297 |
Name of the vaccine | TETRAXIM |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 2 months to 6 years |
Description of the vaccine | DTacP-IPV combined vaccine |
Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
Name of the manufacturing country | Korea, Republic of |
Year of manufacture | 2015 |
Clinical Phase status | Clinical - Phase 4 |
Bacterial strain | Gram-positive bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Given at 2, 4, 6 months (Primary) or 4 to 6 years (Booster) vaccination. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For diphtheria, pertussis and poliomyelitis. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT01437423 |
Reference | NA |
Other name | NA |
Additional Links | NA
|